Eugin Group has acquired Instituto Bernabeu for an undisclosed amount, integrating a prominent European institution specializing in reproductive medicine. Instituto Bernabeu is recognized for its focus on individual solutions in reproductive health and comprehensive women's health services.
The acquired institution has a strong track record in scientific research and innovation. Key milestones include the first IVF pregnancy in Valencia in 1987, pioneering pregnancies with spermatids in Spain, and the world's first births free of retinoschisis and Marfan Syndrome using Preimplantation Genetic Diagnosis (PGD). Instituto Bernabeu has contributed over 200 scientific research papers and operates four facilities in Alicante, Elche, Cartagena, and Benidorm, serving both national and international patients.
This acquisition is strategically significant for Eugin Group, expanding its presence and capabilities within the highly specialized field of reproductive medicine. The integration of Instituto Bernabeu's advanced clinical practices, extensive research portfolio, and established international patient department is expected to enhance Eugin Group's service offerings and geographical reach. Synergies are anticipated through the combination of clinical expertise and research and development efforts.
The transaction underscores a move to consolidate leadership in reproductive health. The combined entity is positioned to leverage shared knowledge and resources to further advance treatment options, expand access to specialized care, and continue its commitment to scientific innovation in reproductive medicine for patients globally.